RhoVac ApS
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Subsidiary
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.rhovac.com
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
Phase 2
Active, not recruiting
- Conditions
- Prostate Cancer Recurrent
- Interventions
- Biological: RV001VOther: Placebo
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- RhoVac APS
- Target Recruit Count
- 180
- Registration Number
- NCT04114825
- Locations
- 🇺🇸
Chesapeake Urology Research Associates, Towson, Maryland, United States
🇺🇸Icahn School of Medicine at Mount Sinai Hospitals, New York, New York, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- Biological: RV001V
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- RhoVac APS
- Target Recruit Count
- 22
- Registration Number
- NCT03199872
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
© Copyright 2025. All Rights Reserved by MedPath